Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 21, 2022 09:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Reports Q3 2022 Compared to Q3 2021 Financial Results

R&D cost reduced in excess of 95% while continuing expansion of our OT-101 clinical programs through our joint ventureG&A cost reduced by approximately 50%Net loss reduced by approximately...